In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

Medicine details

Medicine name:
olaparib (Lynparza)
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Publication due date:
08 November 2021
SMC meeting date:
05 October 2021
Patient group submission deadline:
05 July 2021